Correlation Between Enanta Pharmaceuticals and HUTCHMED DRC
Can any of the company-specific risk be diversified away by investing in both Enanta Pharmaceuticals and HUTCHMED DRC at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enanta Pharmaceuticals and HUTCHMED DRC into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Enanta Pharmaceuticals and HUTCHMED DRC, you can compare the effects of market volatilities on Enanta Pharmaceuticals and HUTCHMED DRC and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enanta Pharmaceuticals with a short position of HUTCHMED DRC. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enanta Pharmaceuticals and HUTCHMED DRC.
Diversification Opportunities for Enanta Pharmaceuticals and HUTCHMED DRC
0.27 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Enanta and HUTCHMED is 0.27. Overlapping area represents the amount of risk that can be diversified away by holding Enanta Pharmaceuticals and HUTCHMED DRC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on HUTCHMED DRC and Enanta Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enanta Pharmaceuticals are associated (or correlated) with HUTCHMED DRC. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of HUTCHMED DRC has no effect on the direction of Enanta Pharmaceuticals i.e., Enanta Pharmaceuticals and HUTCHMED DRC go up and down completely randomly.
Pair Corralation between Enanta Pharmaceuticals and HUTCHMED DRC
Given the investment horizon of 90 days Enanta Pharmaceuticals is expected to under-perform the HUTCHMED DRC. But the stock apears to be less risky and, when comparing its historical volatility, Enanta Pharmaceuticals is 1.29 times less risky than HUTCHMED DRC. The stock trades about -0.5 of its potential returns per unit of risk. The HUTCHMED DRC is currently generating about -0.11 of returns per unit of risk over similar time horizon. If you would invest 1,838 in HUTCHMED DRC on September 3, 2024 and sell it today you would lose (143.00) from holding HUTCHMED DRC or give up 7.78% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Enanta Pharmaceuticals vs. HUTCHMED DRC
Performance |
| Timeline |
| Enanta Pharmaceuticals |
| HUTCHMED DRC |
Enanta Pharmaceuticals and HUTCHMED DRC Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Enanta Pharmaceuticals and HUTCHMED DRC
The main advantage of trading using opposite Enanta Pharmaceuticals and HUTCHMED DRC positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enanta Pharmaceuticals position performs unexpectedly, HUTCHMED DRC can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HUTCHMED DRC will offset losses from the drop in HUTCHMED DRC's long position.| Enanta Pharmaceuticals vs. Monte Rosa Therapeutics | Enanta Pharmaceuticals vs. Design Therapeutics | Enanta Pharmaceuticals vs. Werewolf Therapeutics | Enanta Pharmaceuticals vs. Ikena Oncology |
| HUTCHMED DRC vs. Connect Biopharma Holdings | HUTCHMED DRC vs. Acumen Pharmaceuticals | HUTCHMED DRC vs. Nuvation Bio | HUTCHMED DRC vs. Eledon Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |